It can sometimes be tough to fill prescriptions for GLP-1 drugs like Wegovy and Zepbound, given the overwhelming popularity of the breakthrough weight-loss meds. But people who miss a dose here and there shouldn’t worry about losing ground in their fight against excess weight, a new study says. Folks on GLP-1 drugs can expect to maintain their weight loss if they have a disruption in access, as long as they’ve also adopted healthy lifestyle habits like eating right and exercising, researchers reported at the Endocrine Society’s annual meeting in San Francisco. “While unpredictable GLP-1 medication access is frustrating, the good news is that our research shows effective weight loss can still be achieved if paired with appropriate lifestyle changes and coaching support,” lead researcher Kaelen Medeiros, director of data and research at the private weight-loss company Calibrate in New York City, said in a news release. Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. The drugs’ effectiveness in battling obesity has made them wildly popular, resulting in occasional shortages, Medeiros said. They’re also pricey, which means some insurance companies have instituted strict coverage guidelines. “Patients taking GLP-1 treatments like semaglutide (Ozempic/Wegovy) and tirzepatide (Zepbound) often face challenges consistently accessing their medications due to supply shortages or insurance coverage obstacles,” Medeiros… read on > read on >

















